← Leaderboards
Romain Neugebauer
Kaiser Foundation Research Institute
$2,592,137
Attributed
$5,314,456
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,314,456 · 4
By mechanism
R01$4,083,479 · 2
R56$736,746 · 1
RC1$494,231 · 1
Top collaborators
- Alyce Sophia Adams5 shared
- Jessica Chubak5 shared
- Monique Marie Hedderson2 shared
- Anny H Xiang2 shared
Most similar at Kaiser Foundation Research Institute
Same institution · by research overlap
- Erin Elizabeth Hahn$7,456,765
- Andrew John Karter$16,048,581
- Richard W Grant$15,968,167
- Erin S Leblanc$7,994,574
- Robert B. Penfold$6,971,782
Others in their field
Top investigators on “Race”
- Chanza Baytop · Westat, Inc.$271,217,917
- James E. Gern · University Of Wisconsin-Madison$92,101,481
- Paula Darby Lipman · Westat, Inc.$52,512,411
- Josef Coresh · New York University School Of Medicine$50,787,013
- Linda J Waite · University Of Chicago$46,619,827
- Richard A Miech · Johns Hopkins University$44,656,531
Research focus
RaceFollow-UpTreatment ProtocolsPharmacotherapyDiagnosisMachine LearningAdultClinical DataObesityAffectElectronic Health RecordDoseSample SizeClinical TrialsProviderComplexHealth Care SettingsChemotherapyAnalogChemotherapy Induced NeuropathyCancer EpidemiologyBiometryAdjuvant ChemotherapyCancer Invasiveness
Grant awards (9)
Comparing the effects of pharmacological treatment for gestational diabetes on long-term maternal and child health outcomes$672,314
R01 · FY2025 · DK
Comparing the effects of pharmacological treatment for gestational diabetes on long-term maternal and child health outcomes$670,325
R01 · FY2024 · DK
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$617,580
R01 · FY2024 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$589,573
R01 · FY2023 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$180,606
R01 · FY2022 · CA
Leveraging machine learning to improve risk prediction for chemotherapy inducedneuropathy$689,634
R01 · FY2021 · CA
Leveraging machine learning to improve risk prediction for chemotherapy induced neuropathy$663,447
R01 · FY2020 · CA
Drug Benefit Design and Adherence Disparities in Older Adults$736,746
R56 · FY2019 · AG · contact PI
Effectiveness of Immediate vs. Delayed Use of Metformin in New-Onset T2 Diabetes$494,231
RC1 · FY2010 · DK · contact PI